BE880905A - Compositions influencant le systeme nerveux central et leur methode d'utilisation - Google Patents

Compositions influencant le systeme nerveux central et leur methode d'utilisation

Info

Publication number
BE880905A
BE880905A BE0/198784A BE198784A BE880905A BE 880905 A BE880905 A BE 880905A BE 0/198784 A BE0/198784 A BE 0/198784A BE 198784 A BE198784 A BE 198784A BE 880905 A BE880905 A BE 880905A
Authority
BE
Belgium
Prior art keywords
nervous system
central nervous
influencing
compositions
compositions influencing
Prior art date
Application number
BE0/198784A
Other languages
English (en)
Original Assignee
Merz & Cy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Cy filed Critical Merz & Cy
Publication of BE880905A publication Critical patent/BE880905A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE0/198784A 1978-12-27 1979-12-27 Compositions influencant le systeme nerveux central et leur methode d'utilisation BE880905A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856393A DE2856393C2 (de) 1978-12-27 1978-12-27 Arzneimittel zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
BE880905A true BE880905A (fr) 1980-06-27

Family

ID=6058522

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/198784A BE880905A (fr) 1978-12-27 1979-12-27 Compositions influencant le systeme nerveux central et leur methode d'utilisation

Country Status (10)

Country Link
US (1) US4273774A (fr)
JP (1) JPS5589219A (fr)
BE (1) BE880905A (fr)
CA (1) CA1121726A (fr)
DE (1) DE2856393C2 (fr)
FR (1) FR2445145A1 (fr)
GB (1) GB2044098B (fr)
NL (1) NL7909307A (fr)
SE (1) SE448517B (fr)
SG (1) SG3185G (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33080E (en) * 1981-08-31 1989-10-03 Exxon Research And Engineering Company Adamantane catalyzed paraffin isomerization
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
JP2006527774A (ja) * 2003-06-16 2006-12-07 アラーガン、インコーポレイテッド メマンチン経口製剤
US20050113458A1 (en) * 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
AU2005204358B2 (en) * 2004-01-05 2008-09-04 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate Alzheimer's disease
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
JP2008503475A (ja) * 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
CA2578953A1 (fr) * 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine pour le traitement des troubles du comportement de l'enfant
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2008005534A2 (fr) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
US7985753B2 (en) 2006-08-04 2011-07-26 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
US20080108643A1 (en) * 2006-11-03 2008-05-08 Forest Laboratories Holdings Limited Method for treating autism
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (fr) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
WO2011127235A1 (fr) 2010-04-07 2011-10-13 Eisai Inc. Polythérapie pour le traitement de la démence
WO2012052451A1 (fr) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate
JP5848768B2 (ja) 2010-10-29 2016-01-27 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． インドール誘導体及びその製造方法
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
WO2012085166A1 (fr) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs glutamatergiques métabotropes
WO2012152854A1 (fr) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
EP3102186B1 (fr) 2014-02-04 2021-01-27 Forest Laboratories Holdings Limited Compositions de donépézil et procédé de traitement de la maladie d'alzheimer
WO2016205739A1 (fr) 2015-06-19 2016-12-22 Belew Mekonnen Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
WO2017223402A1 (fr) 2016-06-23 2017-12-28 Corium International, Inc. Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
US10945968B2 (en) 2016-07-27 2021-03-16 Corium, Inc. Memantine transdermal delivery systems
CA3031944A1 (fr) 2016-07-27 2018-02-01 Corium International, Inc. Systemes d'administration transdermique a pharmacocinetique bioequivalent a l'administration orale
AU2017301928B2 (en) 2016-07-27 2023-04-06 Corium, LLC. Donepezil transdermal delivery system
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
US20250161238A1 (en) 2022-02-08 2025-05-22 Fikret Sahin NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864489A (en) * 1972-03-20 1975-02-04 Gen Foods Corp Treatment of hyperkinetic conditions with caffeine
CH603545A5 (fr) * 1972-04-20 1978-08-31 Merz & Co
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
DE2518677A1 (de) * 1974-05-06 1975-11-20 Sandoz Ag Neue pharmazeutische zubereitungen

Also Published As

Publication number Publication date
GB2044098B (en) 1983-01-26
US4273774A (en) 1981-06-16
GB2044098A (en) 1980-10-15
SE7910501L (sv) 1980-06-28
FR2445145A1 (fr) 1980-07-25
SG3185G (en) 1985-06-14
JPS5589219A (en) 1980-07-05
CA1121726A (fr) 1982-04-13
DE2856393C2 (de) 1983-04-28
SE448517B (sv) 1987-03-02
DE2856393A1 (de) 1980-07-03
NL7909307A (nl) 1980-07-01
FR2445145B1 (fr) 1984-10-26

Similar Documents

Publication Publication Date Title
MA19845A1 (fr) Nouvelles piperidinamines et leur preparation
FI801521A7 (fi) Foerfarande foer rening av fosforsyra med avseende pao tungmetaller
FR2504931B1 (fr) Ionomeres modifies, leur preparation et leur utilisation
BE896993A (fr) FACTEURS 1,2,3,4 et 5 DE TEICHOMYCINE A2, LEUR PREPARATION ET LEUR UTILISATION
PT76528B (fr) Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
BE866841A (fr) Procede de preparation d'imidazoazines et -diazines substituees et leur utilisation
TR20880A (tr) Akrilonitrilin aritilmasi
BE883978A (fr) Bouclier d'attaque
BE890465A (fr) Prothese d'osselets
BE882010A (fr) Tetrahydrobenzothiazolylimidazolidinones et leur utilisation
BE896668A (fr) Iminoderives substitues du dihydrobenzopyranne et du dihydrobenzothiopyranne et leur preparation.
BE894056A (fr) 2-oxo-azetidines, leur preparation et leur utilisation
BE891585A (fr) 5 alpha-androstane-17 beta-carboxylates et 5 beta-androstane-17 beta-carboxylates, leur preparation et leur utilisation
FR2508188B1 (fr) Compositions photosensibles et leur utilisation
FR2322849A1 (fr) Preparation d'aminals et leur utilisation comme pesticides
BE890376R (fr) Preparation d'acetaldehyde
BE888608A (fr) Esters de steroide-oxazoles, leur preparation et leur utilisation,
FR2529205B1 (fr) Furfurylamides d'acides phenoxyphenoxyalcanoiques et leur utilisation comme herbicides selectifs
BE891393A (fr) Esthers d'hydroxymethylpyrazines substituees leur preparation et leur utilisation therapeutique
PH16910A (en) Substituted quinazolinones and method of use thereof
DE3361290D1 (de) Preparation of cyanobenzoic-acid esters
BE895664A (fr) Esters d'acides phenoxyphenoxypropioniques leur preparation et leur utilisation
BE895662A (fr) Esters heterocycliques d'acides phenoxybenzoiques, leur preparation et leur utilisation
BE887112A (fr) Carnitinamides d'aminoacides optiquement actifs et leur preparation
BE887203A (fr) Isoxazolyl- et isoxazolinyl-prostaglandines et leur preparation

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: MERZ & CY

Effective date: 19911231